Dehui Zou

Treatment of Patients with Relapsed or Refractory Mantle–Cell Lymphoma with Zanubrutinib, a Selective Inhibitor of Bruton's Tyrosine Kinase

Yuqin Song, Keshu Zhou, Dehui Zou et al. · Clinical Cancer Research · 2020 · 176 citations

Treatment of relapsed or refractory classical Hodgkin lymphoma with the anti-PD-1, tislelizumab: results of a phase 2, single-arm, multicenter study

Yuqin Song, Quanli Gao, Huilai Zhang et al. · Leukemia · 2019 · 153 citations · Full text

Zanubrutinib in relapsed/refractory mantle cell lymphoma: long-term efficacy and safety results from a phase 2 study

Yuqin Song, Keshu Zhou, Dehui Zou et al. · Blood · 2022 · 143 citations · Full text

Long-term Efficacy, Pathology, Pharmacotherapy +17

Efficacy and safety of CD19 CAR T constructed with a new anti-CD19 chimeric antigen receptor in relapsed or refractory acute lymphoblastic leukemia

Runxia Gu, Fang Liu, Dehui Zou et al. · Journal of Hematology & Oncology · 2020 · 107 citations · Full text

Elevated neutrophil-to-lymphocyte ratio and monocyte-to-lymphocyte ratio and decreased platelet-to-lymphocyte ratio are associated with poor prognosis in multiple myeloma

Lihui Shi, Xiaoqi Qin, Huijun Wang et al. · Oncotarget · 2016 · 105 citations · Full text

Prognosis, Immunology, Pathology +16